Novel LDL-oriented pharmacotherapeutical strategies

Pharmacological Research

Volumn 65, Issue 4, 2012, Pages 402-410

  Huang, Lin Zhang ^a   Zhu, Hai Bo ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Agents; Cardiovascular disease; Dyslipidemia; Hypercholesterolemia; LDL; Lipid lowering

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; APOLIPOPROTEIN B; BILE ACID SEQUESTRANT; CARRIER PROTEIN; EPROTIROME; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAPAQUISTAT; LAROPIPRANT; LEVOTHYROXINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRANSFER PROTEIN; MIPOMERSEN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PACTIMIBE; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; SIMVASTATIN; SQUALENE SYNTHASE INHIBITOR; THYROMIMETIC AGENT; UNCLASSIFIED DRUG; WARFARIN;

ABDOMINAL PAIN; ATHEROSCLEROSIS; BLOATING; CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG INHIBITION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENTEROHEPATIC CIRCULATION; ENZYME INHIBITION; FAMILIAL HYPERCHOLESTEROLEMIA; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRANSAMINASEMIA; INJECTION SITE ERYTHEMA; LIVER TOXICITY; METABOLIC INHIBITION; MONOTHERAPY; MUSCLE DISEASE; MYALGIA; MYOPATHY; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; TREATMENT OUTCOME;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; HUMANS; HYPERCHOLESTEROLEMIA;

EID: 84863404502     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2012.01.007     Document Type: Review

References (105)

1. J.A. Pfefferkorn Novel 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors: a patent review Expert Opin Ther Pat 21 2011 187 203
2. S. Yusuf, S. Reddy, S. Ounpuu, and S. Anand Global burden of cardiovascular diseases. Part I. General considerations, the epidemiologic transition, risk factors, and impact of urbanization Circulation 104 2001 2746 2753 (Pubitemid 33108145)
3. V.L. Roger, A.S. Go, D.M. Lloyd-Jones, R.J. Adams, J.D. Berry, and T.M. Brown Heart disease and stroke statistics - 2011 update: a report from the american heart association Circulation 123 2011 e18 e209
4. M. Florentin, E.N. Liberopoulos, D.P. Mikhailidis, and M.S. Elisaf Emerging options in the treatment of dyslipidemias: a bright future? Expert Opin Emerg Drugs 16 2011 247 270
5. M. Farnier Safety review of combination drugs for hyperlipidemia Expert Opin Drug Saf 10 2011 363 371
6. A. Brautbar, and C.M. Ballantyne Pharmacological strategies for lowering LDL cholesterol: statins and beyond Nat Rev Cardiol 8 2011 253 265
7. A. Endo A gift from nature: the birth of the statins Nat Med 14 2008 1050 1052
8. J.W. Jukema, A.V. Bruschke, A.J. van Boven, J.H. Reiber, E.T. Bal, and A.H. Zwinderman Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The regression growth evaluation statin study (REGRESS) Circulation 91 1995 2528 2540
9. K. Toutouzas, M. Drakopoulou, I. Skoumas, and C. Stefanadis Advancing therapy for hypercholesterolemia Expert Opin Pharmacother 11 2010 1659 1672
10. M.E. Mays, and C.A. Dujovne Pleiotropic effects: should statins be considered an essential component in the treatment of dyslipidemia? Curr Atheroscler Rep 10 2008 45 52 (Pubitemid 351385599)
11. D.N. Kiortsis, T.D. Filippatos, D.P. Mikhailidis, M.S. Elisaf, and E.N. Liberopoulos Statin-associated adverse effects beyond muscle and liver toxicity Atherosclerosis 195 2007 7 16 (Pubitemid 47561937)
12. C.R. Harper, and T.A. Jacobson The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis Curr Opin Lipidol 18 2007 401 408 (Pubitemid 47051918)
13. S. Malik, and M.L. Kashyap Niacin, lipids, and heart disease Curr Cardiol Rep 5 2003 470 476 (Pubitemid 38906894)
14. L.A. Carlson, and L. Oro The effect of nicotinic acid on the plasma free fatty acid; demonstration of a metabolic type of sympathicolysis Acta Med Scand 172 1962 641 645
15. V.S. Kamanna, S.H. Ganji, and M.L. Kashyap The mechanism and mitigation of niacin-induced flushing Int J Clin Pract 63 2009 1369 1377
16. K.G. Parhofer Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia Vasc Health Risk Manag 5 2009 901 908
17. H. Vosper Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parameters Clin Med Insights Cardiol 5 2011 85 101
18. C. Paras, M.M. Hussain, and R.S. Rosenson Emerging drugs for hyperlipidemia Expert Opin Emerg Drugs 15 2010 433 451
19. H.E. Bays, M. Davidson, M.R. Jones, and S.L. Abby Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity c-reactive protein when added to statins in patients with hypercholesterolemia Am J Cardiol 97 2006 1198 1205
20. K. Einarsson, S. Ericsson, S. Ewerth, E. Reihner, M. Rudling, and D. Stahlberg Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism Eur J Clin Pharmacol 40 Suppl 1 1991 S53 S58
21. S.W. Altmann, H.R. Davis, L.J. Zhu, X.R. Yao, L.M. Hoos, and G. Tetzloff Niemann-pick c1 like 1 protein is critical for intestinal cholesterol absorption Science 303 2004 1201 1204 (Pubitemid 38233587)
22. H.R. Davis, L.J. Zhu, L.M. Hoos, G. Tetzloff, M. Maguire, and J.J. Liu Niemann-pick c1 like 1 (npc1l1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis J Biol Chem 279 2004 33586 33592 (Pubitemid 39063007)
23. R.H. Knopp, H. Gitter, T. Truitt, H. Bays, C.V. Manion, and L.J. Lipka Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia Eur Heart J 24 2003 729 741 (Pubitemid 36458985)
24. C.A. Dujovne, M.P. Ettinger, J.F. McNeer, L.J. Lipka, A.P. LeBeaut, and R. Suresh Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia Am J Cardiol 90 2002 1092 1097 (Pubitemid 35335597)
25. J.J.P. Kastelein, F. Akdim, E.S.G. Stroes, A.H. Zwinderman, M.L. Bots, and A.F.H. Stalenhoef Simvastatin with or without ezetimibe in familial hypercholesterolemia N Engl J Med 358 2008 1431 1443 (Pubitemid 351482735)
26. R.S. Birjmohun, B.A. Hutten, J.J. Kastelein, and E.S. Stroes Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials J Am Coll Cardiol 45 2005 185 197 (Pubitemid 40094724)
27. W.S. Harris Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review J Lipid Res 30 1989 785 807 (Pubitemid 19167302)
28. A.C. Rustan, J.O. Nossen, E.N. Christiansen, and C.A. Drevon Eicosapentaenoic acid reduces hepatic synthesis and secretion of triacylglycerol by decreasing the activity of acyl-coenzyme a:1,2-diacylglycerol acyltransferase J Lipid Res 29 1988 1417 1426 (Pubitemid 19013036)
29. H. Sampath, and J.M. Ntambi Polyunsaturated fatty acid regulation of gene expression Nutr Rev 62 2004 333 339 (Pubitemid 39299134)
30. W.S. Harris, H.N. Ginsberg, N. Arunakul, N.S. Shachter, S.L. Windsor, and M. Adams Safety and efficacy of omacor in severe hypertriglyceridemia J Cardiovasc Risk 4 1997 385 391 (Pubitemid 28078682)
31. P. Costet Molecular pathways and agents for lowering LDL-cholesterol in addition to statins Pharmacol Ther 126 2010 263 278
32. R. Do, R.S. Kiss, D. Gaudet, and J.C. Engert Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway Clin Genet 75 2009 19 29
33. T. Nishimoto, Y. Amano, R. Tozawa, E. Ishikawa, Y. Imura, and H. Yukimasa Lipid-lowering properties of tak-475, a squalene synthase inhibitor, in vivo and in vitro Br J Pharmacol 139 2003 911 918 (Pubitemid 36877390)
34. E.A. Stein, H. Bays, D. O'Brien, J. Pedicano, E. Piper, and A. Spezzi Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia Circulation 123 2011 1974 1985
35. N. Griebenow, T. Flessner, A. Buchmueller, M. Raabe, H. Bischoff, and P. Kolkhof Identification and optimization of tetrahydro-2h-3-benzazepin-2-ones as squalene synthase inhibitors Bioorg Med Chem Lett 21 2011 2554 2558
36. K. Ishida, G. Visbal, J.C.F. Rodrigues, J.A. Urbina, W. De Souza, and S. Rozental Two squalene synthase inhibitors, e5700 and er-119884, interfere with cellular proliferation and induce ultrastructural and lipid profile alterations in a candida tropicalis strain resistant to fluconazole, itraconazole, and amphotericin b J Infect Chemother 17 2011 563 570
37. N. Griebenow, A. Buchmueller, P. Kolkhof, J. Schamberger, and H. Bischoff Identification of 4h,6h-[2]benzoxepino[4,5-c][1,2]oxazoles as novel squalene synthase inhibitors Bioorg Med Chem Lett 21 2011 3648 3653
38. M. Ichikawa, A. Yokomizo, M. Itoh, N. Haginoya, K. Sugita, and H. Usui Discovery of atrop fixed alkoxy-aminobenzhydrol derivatives: novel, highly potent and orally efficacious squalene synthase inhibitors Bioorg Med Chem 19 2011 5207 5224
39. M. Ichikawa, A. Yokomizo, M. Itoh, K. Sugita, H. Usui, and H. Shimizu Discovery of a new 2-aminobenzhydrol template for highly potent squalene synthase inhibitors Bioorg Med Chem 19 2011 1930 1949
40. K.F. Buhman, M. Accad, and R.V. Farese Mammalian acyl-CoA:cholesterol acyltransferases Biochim Biophys Acta 1529 2000 142 154
41. T.Y. Chang, C.C. Chang, and D. Cheng Acyl-coenzyme a:cholesterol acyltransferase Annu Rev Biochem 66 1997 613 638
42. K. El Harchaoui, F. Akdim, E.S. Stroes, M.D. Trip, and J.J. Kastelein Current and future pharmacologic options for the management of patients unable to achieve low-density lipoprotein-cholesterol goals with statins Am J Cardiovasc Drugs 8 2008 233 242
43. M.C. Meuwese, E. de Groot, R. Duivenvoorden, M.D. Trip, L. Ose, and F.J. Maritz Acat inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the captivate randomized trial J Am Med Assoc 301 2009 1131 1139
44. K. Takahashi, M. Ohta, Y. Shoji, M. Kasai, K. Kunishiro, and T. Miike Novel acyl-CoA:cholesterol acyltransferase inhibitor: indoline-based sulfamide derivatives with low lipophilicity and protein binding ratio Chem Pharm Bull (Tokyo) 58 2010 1057 1065
45. M. Ohta, K. Takahashi, M. Kasai, Y. Shoji, K. Kunishiro, and T. Miike Novel tetrahydroisoquinoline derivatives with inhibitory activities against acyl-CoA:cholesterol acyltransferase and lipid peroxidation Chem Pharm Bull (Tokyo) 58 2010 1066 1076
46. M. Ogino, S. Fukui, Y. Nakada, R. Tokunoh, S. Itokawa, and Y. Kakoi Discovery of a potent and orally available acyl-CoA:cholesterol acyltransferase inhibitor as an anti-atherosclerotic agent: (4-phenylcoumarin) acetanilide derivatives Chem Pharm Bull (Tokyo) 59 2011 1268 1273
47. Y. Yoshinaka, H. Shibata, H. Kobayashi, H. Kuriyama, K. Shibuya, and S. Tanabe A selective acat-1 inhibitor, k-604, stimulates collagen production in cultured smooth muscle cells and alters plaque phenotype in apolipoprotein e-knockout mice Atherosclerosis 213 2010 85 91
48. T. Ohshiro, D. Matsuda, K. Sakai, C. Degirolamo, H. Yagyu, and L.L. Rudel Pyripyropene a, an acyl-coenzyme a:cholesterol acyltransferase 2-selective inhibitor, attenuates hypercholesterolemia and atherosclerosis in murine models of hyperlipidemia Arterioscler Thromb Vasc Biol 31 2011 1108 1115
49. M.H. Davidson Therapies targeting exogenous cholesterol uptake: new insights and controversies Curr Atheroscler Rep 13 2011 95 100
50. J.P. Davies, B. Levy, and Y.A. Ioannou Evidence for a niemann-pick c (npc) gene family: identification and characterization of npc1l1 Genomics 65 2000 137 145 (Pubitemid 30314421)
51. J.P. Davies, C. Scott, K. Oishi, A. Liapis, and Y.A. Ioannou Inactivation of npc1l1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia J Biol Chem 280 2005 12710 12720
52. H.R. Davis, E.P. Veltri, and 1. Zetia Inhibition of niemann-pick c1 like 1 (npc1l1) to reduce intestinal cholesterol absorption and treat hyperlipidemia J Atheroscler Thromb 14 2007 99 108
53. K.L. Howell, R.J. Devita, M. Garcia-Calvo, R.D. Meurer, J. Lisnock, and H.G. Bull Spiroimidazolidinone npc1l1 inhibitors. Part 2. Structure-activity studies and in vivo efficacy Bioorg Med Chem Lett 20 2010 6929 6932
54. M. Kanou, Y. Nisiwaki, A. Nakano, Y. Sugimoto, Y. Yamanaka, and S. Kondo Discovery of a novel and potent cholesterol absorption inhibitor (cai) as promising orally active lipid lowering drug Atheroscler Suppl 2009 10
55. P. Kumar, A. Singla, O. Hedroug, H. Liu, F. Annaba, and S. Saksena Curcumin down-regulates niemann-pick c1-like 1 expression in intestinal epithelial cells Gastroenterology 136 2009 A567 A568
56. J.L. Betters, and L. Yu Npc1l1 and cholesterol transport FEBS Lett 584 2010 2740 2747
57. S. Warnakula, J. Hsieh, K. Adeli, M.M. Hussain, P. Tso, and S.D. Proctor New insights into how the intestine can regulate lipid homeostasis and impact vascular disease: frontiers for new pharmaceutical therapies to lower cardiovascular disease risk Can J Cardiol 27 2011 183 191
58. M.S. Brown, and J.L. Goldstein A receptor-mediated pathway for cholesterol homeostasis Science 232 1986 34 47 (Pubitemid 16037973)
59. +-dependent bile acid transporter asbt by protein kinase c Am J Physiol Gastrointest Liver Physiol 297 2009 G532 G538
60. B.L. Shneider Intestinal bile acid transport: biology, physiology, and pathophysiology J Pediatr Gastroenterol Nutr 32 2001 407 417 (Pubitemid 32488295)
61. E.Y. Zhang, M.A. Phelps, C. Cheng, S. Ekins, and P.W. Swaan Modeling of active transport systems Adv Drug Deliv Rev 54 2002 329 354 (Pubitemid 34260957)
62. W. Kramer, and H. Glombik Bile acid reabsorption inhibitors (BARI): novel hypolipidemic drugs Curr Med Chem 13 2006 997 1016
63. V. Kolhatkar, L. Diao, C. Acharya, A.D. Mackerell, and J.E. Polli Identification of novel nonsteroidal compounds as substrates or inhibitors of hasbt J Pharm Sci 2011
64. G. Wess, W. Kramer, A. Enhsen, H. Glombik, K.H. Baringhaus, and G. Boger Specific inhibitors of ileal bile acid transport J Med Chem 37 1994 873 875 (Pubitemid 24140854)
65. M.B. Tollefson, S.A. Kolodziej, T.R. Fletcher, W.F. Vernier, J.A. Beaudry, and B.T. Keller A novel class of apical sodium co-dependent bile acid transporter inhibitors: the 1,2-benzothiazepines Bioorg Med Chem Lett 13 2003 3727 3730 (Pubitemid 37206496)
66. S.J. Tremont, L.F. Lee, H.C. Huang, B.T. Keller, S.C. Banerjee, and S.R. Both Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 1) J Med Chem 48 2005 5837 5852 (Pubitemid 41319713)
67. M.C. Lewis, L.E. Brieaddy, and C. Root Effects of 2164u90 on ileal bile acid absorption and serum cholesterol in rats and mice J Lipid Res 36 1995 1098 1105
68. P.A. Dawson Role of the intestinal bile acid transporters in bile acid and drug disposition 2011 p. 169-203
69. J.R. Wetterau, L.P. Aggerbeck, M.E. Bouma, C. Eisenberg, A. Munck, and M. Hermier Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia Science 258 1992 999
70. M.M. Hussain, P. Rava, X. Pan, K. Dai, S.K. Dougan, and J. Iqbal Microsomal triglyceride transfer protein in plasma and cellular lipid metabolism Curr Opin Lipidol 19 2008 277 284 (Pubitemid 351653566)
71. M. Cuchel, L.T. Bloedon, P.O. Szapary, D.M. Kolansky, M.L. Wolfe, and A. Sarkis Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia N Engl J Med 356 2007 148 156 (Pubitemid 46089675)
72. F.F. Samaha, J. McKenney, L.T. Bloedon, W.J. Sasiela, and D.J. Rader Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia Nat Clin Pract Cardiovasc Med 5 2008 497 505
73. T.R. Joy, and R.A. Hegele Microsomal triglyceride transfer protein inhibition: friend or foe? Nat Clin Pract Cardiovasc Med 5 2008 506 508
74. T. Hata, Y. Mera, T. Kawai, Y. Ishii, Y. Kuroki, and K. Kakimoto Jtt-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, ameliorates impaired glucose and lipid metabolism in zucker diabetic fatty rats Diabetes Obes Metab 13 2011 629 638
75. D. Aggarwal, K.L. West, T.L. Zern, S. Shrestha, M. Vergara-Jimenez, and M.L. Fernandez Jtt-130, a microsomal triglyceride transfer protein (mtp) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs BMC Cardiovasc Disord 2005 5
76. W. Tong, E. Paradise, O. Schueller, J. Ferkany, and P. Sweetnam Clinical investigations into the role of mtp in chylomicron formation using slx-4090, an enterocyte-specific inhibitor Atheroscler Suppl 2009 10
77. E. Kim, S. Campbell, O. Schueller, E. Wong, B. Cole, and J. Kuo A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, slx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile J Pharmacol Exp Ther 337 2011 775 785
78. J. Li, B.S. Bronk, J.P. Dirlam, A.E. Blize, P. Bertinato, and B.H. Jaynes In vitro and in vivo profile of 5-[(4′-trifluoromethyl-biphenyl-2- carbonyl)-amino]-1h-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), a novel potent mtp inhibitor for obesity Bioorg Med Chem Lett 17 2007 1996 1999 (Pubitemid 46367656)
79. R.P. Robinson, J.A. Bartlett, P. Bertinato, A.J. Bessire, J. Cosgrove, and P.M. Foley Discovery of microsomal triglyceride transfer protein (mtp) inhibitors with potential for decreased active metabolite load compared to dirlotapide Bioorg Med Chem Lett 21 2011 4150 4154
80. R.Z. Yu, T.W. Kim, A. Hong, T.A. Watanabe, H.J. Gaus, and R.S. Geary Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, isis 301012, targeting human apolipoprotein b-100 Drug Metab Dispos 35 2007 460 468 (Pubitemid 46333910)
81. W.C. Cromwell, R.D. Santos, D.J. Blom, D.A. Marais, R.H. Lachmann, and D. Gaudet Mipomersen, a first-in-class apolipoprotein b synthesis inhibitor, lowers lipoprotein (a) in patients with homozygous familial hypercholesterolemia J Clin Lipidol 4 2010 221
82. J.J. Kastelein, M.K. Wedel, B.F. Baker, J. Su, J.D. Bradley, and R.Z. Yu Potent reduction of apolipoprotein b and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein b Circulation 114 2006 1729 1735 (Pubitemid 44607121)
83. B.M. Mearns Therapy: antisense inhibitor of apo b has potent lipoprotein effects Nat Rev Cardiol 8 2011 364
84. G.E. Hardee, M. Lindholm, H.F. Hansen, M.R. Moller, H. Orum, and T. Koch Pharmacology, target reduction, and drug accumulation after oral feeding of an lna antisense oligonucleotide directed against apo-b 100 Arterioscler Thromb Vasc Biol 30 2010 e250
85. J. Cohen, A. Pertsemlidis, I.K. Kotowski, R. Graham, C.K. Garcia, and H.H. Hobbs Low LDL cholesterol in individuals of african descent resulting from frequent nonsense mutations in pcsk9 Nat Genet 37 2005 161 165
86. G. Lambert Unravelling the functional significance of pcsk9 Curr Opin Lipidol 18 2007 304 309 (Pubitemid 46743055)
87. D.W. Zhang, T.A. Lagace, R. Garuti, Z. Zhao, M. McDonald, and J.D. Horton Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation J Biol Chem 282 2007 18602 18612 (Pubitemid 47100234)
88. J. Li, C. Tumanut, J.A. Gavigan, W.J. Huang, E.N. Hampton, and R. Tumanut Secreted pcsk9 promotes LDL receptor degradation independently of proteolytic activity Biochem J 406 2007 203 207 (Pubitemid 47310950)
89. M.C. McNutt, T.A. Lagace, and J.D. Horton Catalytic activity is not required for secreted pcsk9 to reduce low density lipoprotein receptors in hepg2 cells J Biol Chem 282 2007 20799 20803 (Pubitemid 47099894)
90. M. Abifadel, M. Varret, J.P. Rabes, D. Allard, K. Ouguerram, and M. Devillers Mutations in pcsk9 cause autosomal dominant hypercholesterolemia Nat Genet 34 2003 154 156 (Pubitemid 36666925)
91. J.C. Cohen, E. Boerwinkle, T.H. Mosley Jr., and H.H. Hobbs Sequence variations in pcsk9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
92. Y.G. Ni, S. Di Marco, J.H. Condra, L.B. Peterson, W. Wang, and F. Wang A proprotein convertase subtilisin-like/kexin type 9 (pcsk9)-binding antibody that structurally mimics the egf (a) domain of LDL-receptor reduces free circulating pcsk9 and LDL-cholesterol J Lipid Res 2010
93. C.J. Duff, and N.M. Hooper Pcsk9: an emerging target for treatment of hypercholesterolemia Expert Opin Ther Targets 15 2011 157 168
94. N.G. Seidah Pcsk9 as a therapeutic target of dyslipidemia Expert Opin Ther Targets 13 2009 19 28
95. H. Gullberg, M. Rudling, C. Salto, D. Forrest, B. Angelin, and B. Vennstrom Requirement for thyroid hormone receptor beta in t3 regulation of cholesterol metabolism in mice Mol Endocrinol 16 2002 1767 1777 (Pubitemid 34828087)
96. G.R. Thompson, A.K. Soutar, F.A. Spengel, A. Jadhav, S.J. Gavigan, and N.B. Myant Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo Proc Natl Acad Sci USA 78 1981 2591 2595 (Pubitemid 11067253)
97. K.W. Walton, P.J. Scott, P.W. Dykes, and J.W. Davies The significance of alterations in serum lipids in thyroid dysfunction. II. Alterations of the metabolism and turnover of 131-I-low-density lipoproteins in hypothyroidism and thyrotoxicosis Clin Sci 29 1965 217 238
98. J. Kharlip, and D.S. Cooper Recent developments in hyperthyroidism Lancet 373 2009 1930 1932
99. L. Wikstrom, C. Johansson, C. Salto, C. Barlow, A. Campos Barros, and F. Baas Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor alpha 1 EMBO J 17 1998 455 461 (Pubitemid 28045486)
100. R.E. Weiss, Y. Murata, K. Cua, Y. Hayashi, H. Seo, and S. Refetoff Thyroid hormone action on liver, heart, and energy expenditure in thyroid hormone receptor beta-deficient mice Endocrinology 139 1998 4945 4952 (Pubitemid 28533441)
101. H. Gullberg, M. Rudling, D. Forrest, B. Angelin, and B. Vennstrom Thyroid hormone receptor beta-deficient mice show complete loss of the normal cholesterol 7alpha-hydroxylase (cyp7a) response to thyroid hormone but display enhanced resistance to dietary cholesterol Mol Endocrinol 14 2000 1739 1749
102. A. Berkenstam, J. Kristensen, K. Mellström, B. Carlsson, J. Malm, and S. Rehnmark The thyroid hormone mimetic compound kb2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans Proc Natl Acad Sci USA 105 2008 663 667 (Pubitemid 351171765)
103. P.W. Ladenson, J.D. Kristensen, E.C. Ridgway, A.G. Olsson, B. Carlsson, and I. Klein Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia N Engl J Med 362 2010 906 916
104. C. Chan, D. Andreotti, B. Cox, B.W. Dymock, J.L. Hutson, and S.E. Keeling The squalestatins: decarboxy and 4-deoxy analogues as potent squalene synthase inhibitors J Med Chem 39 1996 207 216 (Pubitemid 26023514)
105. C. Baigent, A. Keech, P.M. Kearney, L. Blackwell, G. Buck, and C. Pollicino Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278